Opendata, web and dolomites

COMBACTE-CDI SIGNED

Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 COMBACTE-CDI project word cloud

Explore the words cloud of the COMBACTE-CDI project. It provides you a very rough idea of what is the project "COMBACTE-CDI" about.

patient    lack    ecdis    evaluation    wp3    executing    antibiotics    health    mean    sensitivity    epidemiological    actively    extensive    exposed    transmission    subjects    input    epidemiology    drivers    multiple    size    contemporaneous    partnered    clinical    true    cdi    platform    lab    interventions    isolates    usually    successfully    food    practices    enhanced    diagnostic    human    strain    wp1    incidence    data    infection    conduct    expertise    models    identification    efpia    brings    followed    laboratory    optimize    imi    diagnosis    market    clin    merger    notably    simulation    imi2    combating    hospitalized    economy    prevention    variations    diagnostics    frequency    authorization    resistance    citizens    excellent    resource    single    individuals    patients    roles    packages    recurrence    definition    effectiveness    wps    infections    scientific    resilience    compare    therapeutic    bacterial    mortality    difficile    playing    limited    impacts    options    settings    prior    economic    community    clustering    underestimated    examined    comprising    quantification    reduce    aid    parallel    quantify    link    provides    trial    experts    wp2    bacte    proof    realization    sensitive    undertaken    net    healthcare    poses    interventional    create    euclid    countries    harmonise    surveillance    first    time    synergistic    collected    assay    combacte    interrelated    animal    wp4    accurate    collaborative    prevalent    questionnaire    costeffectively    feasible    network    clostridium    burden    strategies    guidelines    provision    morbidity    treatment   

Project "COMBACTE-CDI" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.combacte.com/about/combacte-cdi-understanding-of-the-epidemiology-and-clinical-impact-of-clostridium-difficile-infection/
 Total cost 4˙179˙307 €
 EC max contribution 2˙312˙305 € (55%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-09-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 350˙255.00
2    UNIVERSITY OF LEEDS UK (LEEDS) participant 1˙330˙476.00
3    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 151˙848.00
4    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 150˙260.00
5    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 137˙676.00
6    NACIONALNI LABORATORIJ ZA ZDRAVJE, OKOLJE IN HRANO SI (MARIBOR) participant 90˙557.00
7    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 58˙556.00
8    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 42˙676.00
9    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
10    BIOMERIEUX SA FR (Marcy l'Etoile) participant 0.00
11    DA VOLTERRA SAS FR (PARIS) participant 0.00
12    GLAXOSMITHKLINE BIOLOGICALS SA BE (RIXENSART) participant 0.00
13    PFIZER LIMITED UK (SANDWICH) participant 0.00
14    SANOFI PASTEUR SA FR (LYON) participant 0.00

Map

 Project objective

Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients and individuals in the community; notably, there is an increasing realization that cases also occur in subjects not recently exposed to healthcare interventions, including antibiotics. CDI poses an extensive burden of morbidity, mortality and healthcare resource utilization, and so requires effective prevention and management strategies. Epidemiological data are, however, limited and studies typically have examined only part of a healthcare economy and usually have been focused on single countries/healthcare systems. Thus, there is a lack of robust, comprehensive data on the impact of CDI across countries in Europe. Furthermore, we know that large variations in the frequency of testing and the sensitivity of CDI diagnostics across European countries mean that the size of the problem is underestimated.

Combating Bacterial Resistance in Europe-CDI (COMBACTE-CDI) therefore aims to develop a detailed understanding of the epidemiology and clinical impact of CDI across multiple European countries. Our project proposal provides a collaborative approach comprising three scientific work packages (WPs). A large epidemiology study will be undertaken across Europe in WP1 to quantify the burden of CDI (incidence, distribution, recurrence, morbidity, mortality, transmission) across the whole healthcare economy. This will be followed by a case/control study in WP2, which along with data collected in a questionnaire will enable the consortium to assess current practices in Europe (guidelines, testing, surveillance, treatment, cost) and their potential impacts. WP3 will create a rich, European, research platform that will provide support for future proof-of-concept and clinical studies of new prevention and treatment strategies for CDI. The three interrelated research WPs will be supported by a management work package (WP4).

COMBACTE-CDI will harmonise with many of the IMI2 objectives; specifically, we aim to improve the health of European citizens by providing evidence of the true epidemiology and transmission of CDI. We will also develop ‘best-practice’ models for diagnosis, treatment and surveillance, which should reduce the incidence and impact of CDI (including mortality) across Europe, and will optimize patient management. Notably, in order to deliver these aims costeffectively and to test the resilience of our data, we will actively link and compare our data with other European projects that include CDI as a target condition. This synergistic approach will be all the more feasible as the participants in COMBACTE-CDI are playing key roles in multiple, relevant, parallel European CDI activities.

Our ambitious proposal aims to go beyond the state of the art in 8 aspects: quantification of CDI in the whole healthcare economy; contemporaneous comparison with animal and food isolates with those within human health; identification of potential drivers of strain clustering, providing enhanced information to aid further trial/study design and conduct; use of a novel highly sensitive diagnostic assay for more accurate CDI case definition; provision of both cost-effectiveness and transmission models to enable further evaluation of interventions; and finally, by comparing overall costs in different European healthcare settings, we will, for the first time, allow simulation of the economic impact of novel CDI treatment options, even prior to market authorization.

COMBACTE-CDI is the merger of excellent European expertise on the clinical, diagnostic, and therapeutic issues related to CDI and the expertise and input of 7 EFPIA partners. It brings together experts that partnered in CDI projects (EUCLID, ECDIS-NET), the largest existing (IMI-funded) clinical and laboratory network in Europe (CLIN-Net and LAB-Net) for successfully executing challenging epidemiological and interventional studies related to bacte

 Deliverables

List of deliverables.
Report on heterogeneity of testing and delivery of dataset Documents, reports 2020-02-13 13:11:22
Report on current treatment pathways Documents, reports 2020-02-13 13:11:11
Report on high risk groups and delivery of dataset Documents, reports 2020-02-13 13:11:32
Report on recurrent CDI, morbidity and mortality and delivery of dataset Documents, reports 2020-02-13 13:09:19
Report on current surveillance practices Documents, reports 2020-02-13 13:08:54
Report on current guidelines for diagnosis, management and control of CDI Documents, reports 2020-02-13 13:09:23
Report on strain distribution and delivery of dataset Documents, reports 2020-02-13 13:09:02
Full ethical approval of final study protocol from all countries Documents, reports 2020-01-28 14:45:03
Adaptation of COMBACTE website to include COMBACTE-CDI Websites, patent fillings, videos etc. 2020-01-28 14:45:03

Take a look to the deliverables list in detail:  detailed list of COMBACTE-CDI deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COMBACTE-CDI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COMBACTE-CDI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More  

STOPFOP (2019)

Saracatinib Trial tO Prevent FOP

Read More